AstraZeneca And Ionis ATTR Ambitions Boosted

Efficacy of Eplontersen Maintained For 66 Weeks

The companies are hoping that new data on recently-filed eplontersen will boost the drug's chances of challenging Alnylam’s Amvuttra and Onpattro.

DATA_Puzzle Piece_186976547_1200.jpg
More data added in support of eplontersen • Source: Shutterstock

A few weeks after filing eplontersen with regulators in the US, AstraZeneca PLC and Ionis Pharmaceuticals, Inc. have presented positive long-term data for the transthyretin amyloidosis (ATTR) therapy.

At the beginning of March, the companies filed eplontersen with the US Food and Drug Administration for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) on the back of 35-week interim data from the Phase III NEURO-TTRansform trial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.